The biotech investment sector has always been its own market, very distinct from other sectors. So it was no surprise that when most sectors turned slowly upward after the pandemic-inspired crash, Biotech (XBI) rose 164%, exceeding the overall market (SPY) performance by triple digits. Then, about 11 months from biotech’s launch to the stratosphere, it took its own path downward even though the overall market continued upward for another 11 months. In recent weeks the overall market has been trading sideways after hitting a YTD low on June 16th. Over the same short period, the biotech sector has gained double-digits. Read More >>